Abstract Details

Title Use of Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling and Simulations to Predict Efficacy Outcomes with Eslicarbazepine Acetate (ESL) 800mg Once-Daily (QD) as Monotherapy

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) (-)

Poster/Presentation
Number 025

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Soujanya Sunkaraneni PRESENTER	No disclosure on file
	No disclosure on file
Janet K. Pitner, PharmD, MBA (Sunovion Pharmaceuticals, Inc)	No disclosure on file
Todd Grinnell, PhD	Todd Grinnell, PhD has received personal compensation for serving as an employee of Sunovion Pharmaceuticals Inc..
David E. Blum, MD	Dr. Blum has received personal compensation for serving as an employee of Neurona Therapeutics. Dr. Blum has stock in Neurona Therapeutics.

��ɫ��

��ɫ��

Abstract Details

��ɫ����

��ɫ����

��ɫ��

��ɫ��